Veracyte Stock News

Veracyte (VCYT) delivered earnings and revenue surprises of -7.14% and 6.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Veracyte (NASDAQ:VCYT) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.16 (-14.3% Y/Y) and the consensus…

Inogen (INGN) delivered earnings and revenue surprises of -36.49% and 0.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022

Findings shared at 2022 ASCO GU Symposium are from the first late-stage clinical study validating any gene-expression test for this patient group Veracyte, Inc . (NASDAQ: VCYT ) announced that new data validating the clinical utility of the company''s Decipher Prostate Genomic Classifier for guiding treatment selection in men with intermediate-risk prostate cancer will be presented Thursday, February 17, at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium (Poster #M1). The data, from the randomized, Phase 3 NRG/RTOG 0126 study, confirm initial findings that the Decipher Prostate Genomic Classifier is a prognostic biomarker that can help physicians and patients make personalized treatment decisions in the intermediate-risk setting. "These findings represent the first high-level evidence of any genomic classifier in intermediate-risk prostate cancer and demonstrate that the Decipher 22-gene biomarker significantly improves prognostic performance across numerous clinically meaningful endpoints," said Daniel Spratt, M.D., chair of Radiation Oncology at University Hospitals Seidman Cancer Center and professor and chair of the Department of Radiation Oncology at Case Western Reserve University School of Medicine, and lead investigator for the study.

Veracyte Inc. (NASDAQ:VCYT) price on Friday, February 11, fall -2.89% below its previous days close as a downside momentum from buyers pushed the stocks value to $29.94. A look at the stocks price movement, the close in the last trading session was $30.83, moving within a range at $29.48 and $32.555. The beta value (5-Year What Does 2022 Hold For Veracyte Inc. (NASDAQ:VCYT)? Read More »

DexCom (DXCM) delivered earnings and revenue surprises of -20.93% and 0.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference

Veracyte <> said new data suggests that its Percepta Genomic Sequencing Classifier ((GSC)) test can accelerate delivery of curative therapy for patients with high-risk lung

The stock market and bond market remain historically overvalued today, however, the almost all-encompassing bubble has started to break. Learn more here.

Veracyte (VCYT) announces key leadership promotions that further position the company to achieve its strategic global vision.Effective immediately, Tina Nova, Ph.D., is President

Veracyte, Inc. (NASDAQ:VCYT) rose 3.4% on Wednesday . The company traded as high as $45.14 and last traded at $44.79. Approximately 6,255 shares were traded during trading, a decline of 99% from the average daily volume of 757,466 shares. The stock had previously closed at $43.30. VCYT has been the subject of a number of []